Unicycive Therapeutics, Inc.
UNCY
Nasdaq
Manufacturing
Chemicals
€ 6,63
▼
€ 0,02
(-0,30%)
Marktkapitalisatie: 168,84 M
Prijs
€ 6,69
Marktkapitalisatie
168,84 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—
Koershistorie
Financiële Trends
No fundamental snapshot available yet.
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 675.000,0 | 675.000,0 | 951.000,0 | — |
| Net Income | -26,56 M | -36,73 M | -30,54 M | -18,06 M | -10,02 M |
| EPS (Diluted) | -1,67 | -0,56 | -1,28 | -1,20 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -29,52 M | -32,12 M | -20,77 M | -18,05 M | -8,98 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 9,12 M | 20,01 M | 12,90 M | 12,44 M | 6,08 M |
| SG&A Expenses | — | — | — | 383.000,0 | 245.000,0 |
| D&A | — | — | — | 428.000,0 | — |
| Interest Expense | 71.000,0 | 71.000,0 | 82.000,0 | 6.000,0 | 628.000,0 |
| Income Tax | — | — | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 49,14 M | 31,67 M | 14,19 M | 2,82 M | 18,74 M |
| Total Liabilities | 18,94 M | 24,24 M | 18,00 M | 3,28 M | 2,26 M |
| Shareholders' Equity | 30,20 M | 7,43 M | -3,81 M | -466.000,0 | 16,48 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 29,20 M | — | — | 455.000,0 | 16,58 M |
| Current Assets | 48,96 M | 30,95 M | 13,40 M | 2,64 M | 18,41 M |
| Current Liabilities | 18,94 M | 24,12 M | 17,53 M | 3,28 M | 2,11 M |
{"event":"ticker_viewed","properties":{"ticker":"UNCY","listing_kind":"stock","pathname":"/stocks/uncy","exchange":"Nasdaq","country":"US"}}